Table 1 Patient demographic and clinical characteristics
Sample characteristics | Stage 1 (n = 14) | Stage 2 (n = 18) | |
|---|---|---|---|
Recruitment source | |||
MDS Foundation | 6 (43%) | 11 (61%) | |
Physician referral | 8 (57%) | 7 (39%) | |
Diagnosis type | |||
Higher-risk MDS | 11 (79%) | 14 (78%) | |
Low-blast count AML | 1 (7%) | 1 (6%) | |
CMML | 2 (14%) | 3 (17%) | |
Age, years | |||
Mean (SD) | 68.8 (±8.48) | 68.1 (±10.1) | |
Minimum | 54 | 50 | |
Maximum | 83 | 83 | |
Gender | |||
Female | 9 (64%) | 10 (56%) | |
Male | 5 (36%) | 8 (44%) | |
Education level | |||
Post-graduate degree | 5 (36%) | 5 (28%) | |
Undergraduate degree | 1 (7%) | 1 (6%) | |
Some college | 3 (21%) | 3 (17%) | |
Trade/technical degree | 0 (0%) | 1 (6%) | |
High school/General Educational Development equivalent | 4 (29%) | 6 (33%) | |
Some high school or less | 1 (7%) | 2 (12%) | |
Employment status | |||
Retired | 8 (57%) | 10 (56%) | |
Part-time | 3 (21%) | 3 (17%) | |
Full-time | 2 (14%) | 1 (6%) | |
Disability | 1 (7%) | 3 (17%) | |
Not employed | 0 (0%) | 1 (6%) | |
Eastern Cooperative Oncology Group status | |||
Clinician-reported | 0 – fully active | 1 (7%) | 1 (6%) |
1 – restricted in physically strenuous activity | 7 (50%) | 6 (33%) | |
Patient-reported | 1 – difficulty with physically strenuous activity | 1 (17%) | 5 (28%) |
2 – able to walk and care for self, restricted in work activities | 5 (36%) | 6 (33%) | |
Classification (clinician-reported only) | n = 8 | n = 7 | |
FAB- Refractory anemia | 1 (13%) | 1 (14%) | |
WHO-RAEB1 | 3 (38%) | 2 (29%) | |
WHO-RAEB2 | 1 (13%) | 1 (14%) | |
FAB- Refractory anemia, WHO RAEB1 | 2 (25%) | 2 (29%) | |
FAB-CMML and WHO-CMML1 | 1 (12%) | 1 (14%) | |
Prognostic risk categoryb (MDS only) | n = 11 | n = 10 | |
Very high | 4 (36%) | 3 (30%) | |
High | 3 (27%) | 3 (30%) | |
Intermediate | 2 (18%) | 2 (20%) | |
Unknown | 2 (18%) | 2 (20%) | |
Hemoglobin level | |||
7.0–9.9 | 6 (43%) | 9 (50%) | |
10.0–11.9 | 6 (43%) | 6 (33%) | |
12.0–13.0 | 2 (14%) | 3 (17%) | |
% myeloblasts in bone marrow (patient-reported only) | n = 6 | n = 10 | |
< 1% | 1 (17%) | 1 (10%) | |
1–9.9% | 3 (50%) | 5 (50%) | |
10–11% | 1 (17%) | 1 (10%) | |
Missing data | 1 (17%) | 3 (30%) | |
Treatmenta | |||
Azacitidine | 9 (64%) | 12 (67%) | |
Decitabine | 2 (14%) | 2 (11%) | |
G-CSF; copper gluconate; ondansetron; sulfamethoxazole / trimethoprim; levofloxacin; valacyclovir; acetaminophen/hydrocodone; oxycodone; prochlorperazine | 1 (7%) each | 1 (6%) each | |
Unidentified clinical trial study drug | 0 (0%) | 1 (6%) | |
No treatment | 0 (0%) | 1 (6%) | |